Market Insights

  Dry eye syndrome results in irritated and burning eyes due to lack of tear production and moisturization. Meibomian Gland Dysfunction has more prevalence among the geriatric population. The market consists of several products used in therapeutics, such as cyclosporine, topical corticosteroids, punctal plugs, omega supplements, and the especially popular artificial tears. Fast approval and launch of products used for dry eye treatment is expected to drive market growth in future. Several key market players are focused on collaborative product development, innovation, and expansion of product portfolio. For instance, in October 2020, Santen Pharmaceutical and Orbis International announced their long-term collaboration for ten years to contribute toward the increasing burden of eye diseases in low- and middle-income countries. Rapidly increasing number of eye care centers due to rising focus on primary eye care is expected to propel dry eye syndrome treatment market growth. Increasing n

  Interventional pulmonology is an area of pulmonary medicine that deals specifically with minimally invasive endoscopic and percutaneous procedures for the diagnosis and treatment of neoplastic as well as non-neoplastic diseases of the airways, lungs, and pleura. Rise in the number of COPD cases across the world is expected to boost demand over the coming years. Need for faster recovery time and reduced pain during procedures and surgeries for respiratory disorders has strengthened the market. Leading manufacturers of interventional pulmonology devices are focusing on geographical expansion to increase revenue and add new repair and service centers in emerging countries through the acquisition of local players. Various awareness programs have been initiated by healthcare providers and health organizations/societies such as environmental programs, medication maintenance programs, and online education programs for public and healthcare professionals across the globe to control asthma, C

  Peptones are protein hydrolysates that are widely used as a growth supplement for mammalian and microbial cell culture. These are derived from plants, animals, and yeast. However, animal-based peptones are mostly preferred for in commercial cell culture optimization processes. Availability of a wide variety of animal peptones also contributes to their high-value share in the market. Increasing adoption of animal-based peptones as a low-cost growth supplement for the commercial production of biopharmaceuticals is accelerating market growth. Further, growing biopharmaceutical manufacturing activities are also expected to accelerate the expansion of the peptone market over the forecast period of 2020 to 2030. Growing burden of chronic disease patient population is creating huge demand for novel biopharmaceuticals. Protein supplements such as peptone play an important role in biopharmaceutical manufacturing. Due to rapid growth of the biopharmaceutical industry, demand for peptone is exp

  Phenylketonuria (PKU) is an inherited disorder caused by excess of phenylalanine in the blood, which can lead to severe intellectual disabilities. There is no cure for phenylketonuria as yet, and dietary management is the only option to maintain the phenylalanine level in the body. Untreated infants with PKU tend to have unusually light eye, skin, and hair colour due to excess of phenylalanine levels interfering with melanin. Neurological symptoms such as seizures, abnormal muscle movement, tremors, or involuntary movement are some of the symptoms mainly observed in such patients. Rising prevalence of phenylketonuria among newborns and surging demand for novel formulations to treat the disease have led to increased opportunities for market players. Stakeholders are investing more in research & development for novel treatment solutions within the nutraceutical industry. Get Sample Copy of Report @  https://www.persistencemarketresearch.com/samples/14410 Companies covered in Phenyl

  Antibiotic resistance is one of the biggest public health concerns today. In the U.S., over 2 million people suffer from an antibiotic-resistant infection annually. Growing mortality rate due to these infections has generated a gateway for pharmaceutical manufacturers to develop novel antibiotics. Fighting this threat is a national and public health priority that needs a collaborative approach among healthcare providers and governments. Human overuse of antibiotics leads to the development of antibiotic resistance, which, in turn, demands newer antibiotics. Escherichia coli and Klebsiella pneumonia are highly resistant to the class of antibiotics called Carbapenem. Carbapenem-resistant Enterobacteriaceae (CRE) infection is a dangerous condition, because these microbes can cause infections in almost all parts of the body. Some of the very severe and common infections include urinary tract infections, ventilator-associated pneumonia bloodstream infections, and intra-abdominal abscesses